Eligibility [hlca]
bevacizumab [aapp, imft, phsu]
Independent [idcn]
Prognostic Factor [clna]
Patients [podg]
Advanced [qlco]
Non-Small Cell Lung Cancer [neop]
Squamous [qlco]
Retrospective Cohort Study [resa]
bevacizumab [aapp, imft, phsu]
Unique [qlco]
eligibility criteria [qlco]
absence [qnco]
Haemoptysis [sosy]
Blood Vessel [bpoc]
Invasion [fndg]
prognostic [inpr]
IMPACT [gngm]
bevacizumab [aapp, imft, phsu]
Specific [qlco]
criteria [inpr]
Evaluated [ftcn]
Methods [inpr]
Patients [podg]
Stage IV [inpr]
Non-Small Cell Lung Cancer [neop]
Squamous [qlco]
Started [qlco]
Chemotherapy [topp]
Approval [qlco]
bevacizumab [aapp, imft, phsu]
reviewed [inpr]
Patients [podg]
Impaired [ftcn]
Organ [bpoc]
function [phsf]
poor performance status [patf]
untreated [fndg]
Symptomatic [ftcn]
Brain Metastasis [neop]
Excluded [idcn]
Evaluation [ftcn]
bevacizumab [aapp, imft, phsu]
Eligibility [hlca]
Compared [acty]
Survival [acty]
treatment failure [qlco]
Patients [podg]
eligible [idcn]
Group A [clas]
Group [idcn]
Receive [qlco]
bevacizumab [aapp, imft, phsu]
Patients [podg]
stage IV non-small cell lung cancer [neop]
Squamous [qlco]
Eligibility [hlca]
bevacizumab [aapp, imft, phsu]
Evaluated [ftcn]
Patients [podg]
Seven [qnco]
Patients [podg]
considered [idcn]
Group [idcn]
Based [ftcn]
History [ocdi]
Haemoptysis [sosy]
N NOS [aapp, imft]
Blood Vessel [bpoc]
Invasion [fndg]
N NOS [aapp, imft]
Cardiovascular disease [dsyn]
N NOS [aapp, imft]
Remaining [qlco]
Patients [podg]
Classified [clas]
Group A [clas]
Survival [acty]
Group A [clas]
months [tmco]
Group [idcn]
months [tmco]
P NOS [aapp, imft]
treatment failure [qlco]
Long [qlco]
Group A [clas]
6 9 [fndg]
months [tmco]
Group [idcn]
3 Months [tmco]
P NOS [aapp, imft]
Adjusted [ftcn]
Hazard Ratio [qnco]
bevacizumab [aapp, imft, phsu]
Eligibility [hlca]
Survival [acty]
treatment failure [qlco]
Confidence Intervals [qnco]
Eligibility [hlca]
bevacizumab [aapp, imft, phsu]
Represent [acty]
Power [hcpp]
Prognostic Factor [clna]
Patients [podg]
Squamous [qlco]
Non-Small Cell Lung Cancer [neop]
Proportion [qnco]
Patients [podg]
Line [spco]
Chemotherapy [topp]
Disease Progression [patf]
Unacceptable [qlco]
toxicity [qlco]
Biased [idcn]
bevacizumab [aapp, imft, phsu]
Eligibility [hlca]
Selection Bias [qnco]
Large [qnco]
Clinical Trials [resa]
bevacizumab [aapp, imft, phsu]
findings [ftcn]
Trial [resa]
interpreted [ftcn]
Extreme [qlco]
